Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nadja Kopp

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
The Journal of Experimental Medicine|January 25, 2012
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibitionOliver Weigert, Andrew A Lane, Liat Bird, et al.
Nature Medicine|December 9, 2014
Mutations in G protein β subunits promote transformation and kinase inhibitor resistanceAkinori Yoda, Guillaume Adelmant, Jerome Tamburini, et al.
The Lancet. Oncology|August 11, 2015
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryAlessandro Pastore, Vindi Jurinovic, Robert Kridel, et al.
Cancer Cell|July 16, 2015
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic LeukemiaShuo-Chieh Wu, Loretta S Li, Nadja Kopp, et al.
Cancer Cell|April 13, 2016
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in MiceElizabeth C Townsend, Mark A Murakami, Alexandra Christodoulou, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
The Journal of Experimental Medicine|January 25, 2012
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibitionOliver Weigert, Andrew A Lane, Liat Bird, et al.
Nature Medicine|December 9, 2014
Mutations in G protein β subunits promote transformation and kinase inhibitor resistanceAkinori Yoda, Guillaume Adelmant, Jerome Tamburini, et al.
The Lancet. Oncology|August 11, 2015
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryAlessandro Pastore, Vindi Jurinovic, Robert Kridel, et al.
Cancer Cell|July 16, 2015
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic LeukemiaShuo-Chieh Wu, Loretta S Li, Nadja Kopp, et al.
Cancer Cell|April 13, 2016
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in MiceElizabeth C Townsend, Mark A Murakami, Alexandra Christodoulou, et al.
Pageof 2